Headlines about Pfizer (NYSE:PFE) have been trending positive on Saturday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pfizer earned a daily sentiment score of 0.31 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.6849132710147 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern’s rankings:
Shares of Pfizer (PFE) traded down $0.02 during trading hours on Friday, reaching $35.18. 15,045,100 shares of the company were exchanged, compared to its average volume of 20,361,484. The company has a market capitalization of $209,816.89, a PE ratio of 14.08, a price-to-earnings-growth ratio of 2.49 and a beta of 1.01. Pfizer has a fifty-two week low of $30.51 and a fifty-two week high of $36.78. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.34 and a quick ratio of 1.06.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.67%. The company’s revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.61 earnings per share. sell-side analysts predict that Pfizer will post 2.59 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a dividend of $0.32 per share. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.64%. Pfizer’s payout ratio is presently 79.01%.
Several brokerages have recently weighed in on PFE. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, August 14th. Jefferies Group LLC set a $35.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Thursday, August 24th. Berenberg Bank reiterated a “hold” rating and issued a $36.00 target price (down from $39.00) on shares of Pfizer in a research note on Tuesday, August 15th. Deutsche Bank AG set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. Finally, Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Friday, July 14th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company. Pfizer currently has an average rating of “Hold” and an average price target of $38.48.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/11/pfizer-pfe-getting-favorable-press-coverage-analysis-finds.html.
In related news, insider Laurie J. Olson sold 8,064 shares of the business’s stock in a transaction on Monday, August 21st. The shares were sold at an average price of $32.70, for a total value of $263,692.80. Following the transaction, the insider now owns 74,506 shares in the company, valued at $2,436,346.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total transaction of $262,027.50. Following the completion of the transaction, the executive vice president now owns 117,432 shares in the company, valued at approximately $4,186,450.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 374,621 shares of company stock worth $12,796,098. 0.06% of the stock is owned by company insiders.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.